Skip to content

Effect of hepatitis B immunoglobulin withdrawal on recurrence of hepatitis B in liver transplant recipients

Effect of hepatitis B immunoglobulin withdrawal on recurrence of hepatitis B in liver transplant recipients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035793
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B recurrence after liver transplantation

Interventions

Group 1:Withdraw hepatitis B immune globulin after short term use
Group 2:Hepatitis B therapy with Tenofovir Alafenamide Fumarate

Sponsors

Zhongshan Hospital, Fudan University, Shanghai,China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Male or non-pregnant female patients aged between 18 and 65 years; 2) The donor liver is negative for HBeAg and HBsAg, and other virological examinations meet the criteria of the donor liver; 3) The subjects receive liver transplantation for the first time, the primary disease is hepatitis B-related liver disease, and the liver cancer patients are within the "Fudan Standard"; 4) One month after transplantation, total bilirubin =100 IU/L; HBV-DNA below the detection limit; 5) Patients voluntarily participate in the research with good compliance.

Exclusion criteria

Exclusion criteria: 1) Patients with severe heart, lung, and kidney diseases; 2) Primary liver cancer has invaded large vessels such as vena cava, main trunk or left and right branches of portal vein, and hepatic vein; 3) Serious transplant-related complications (such as severe acute rejection, bile duct and vascular complications require intervention or surgery) after transplantation; 4) The patients have other types of viral hepatitis; 5) Retransplantation or combined organ transplantation; 6) Allergic to HBIG; 7) Participated in other clinical trials in the last 3 months; 8) No legal capacity or limited legal capacity; 9) Any other circumstances that the investigator considers the patients inappropriate to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Cumulative recurrence rate of hepatitis B;

Secondary

MeasureTime frame
Adverse events related to hepatitis B treatment;Patients’ overall survival (OS);Changes in subjects' quality of life;

Countries

China

Contacts

Public ContactHe Yifeng

Zhongshan Hospital, Fudan University

he.yifeng@zs-hospital.sh.cn+86 13788904072

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026